Bridgebio Oncology Therapeutics, Inc. (BBOT)
4.665
-0.10
(-2.20%)
USD |
NASDAQ |
Sep 21, 11:54
Bridgebio Oncology Therapeutics Enterprise Value : 158.95M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 158.95M |
| September 17, 2026 | 168.57M |
| September 16, 2026 | 158.15M |
| September 15, 2026 | 167.76M |
| September 14, 2026 | 181.38M |
| September 11, 2026 | 173.37M |
| September 10, 2026 | 219.04M |
| September 09, 2026 | 317.98M |
| September 08, 2026 | 486.62M |
| September 04, 2026 | 496.24M |
| September 03, 2026 | 489.83M |
| September 02, 2026 | 489.03M |
| September 01, 2026 | 483.42M |
| August 31, 2026 | 481.82M |
| August 28, 2026 | 477.01M |
| August 27, 2026 | 512.26M |
| August 26, 2026 | 518.67M |
| August 25, 2026 | 527.48M |
| August 24, 2026 | 509.05M |
| August 21, 2026 | 504.25M |
| August 20, 2026 | 504.25M |
| August 19, 2026 | 545.91M |
| August 18, 2026 | 493.83M |
| August 17, 2026 | 501.04M |
| August 14, 2026 | 502.64M |
| Date | Value |
|---|---|
| August 13, 2026 | 516.26M |
| August 12, 2026 | 531.49M |
| August 11, 2026 | 513.86M |
| August 10, 2026 | 520.27M |
| August 07, 2026 | 524.28M |
| August 06, 2026 | 480.21M |
| August 05, 2026 | 494.63M |
| August 04, 2026 | 487.42M |
| August 03, 2026 | 437.75M |
| July 31, 2026 | 424.93M |
| July 30, 2026 | 457.78M |
| July 29, 2026 | 436.55M |
| July 28, 2026 | 464.99M |
| July 27, 2026 | 477.81M |
| July 24, 2026 | 483.42M |
| July 23, 2026 | 475.41M |
| July 22, 2026 | 489.83M |
| July 21, 2026 | 475.41M |
| July 20, 2026 | 451.37M |
| July 17, 2026 | 462.59M |
| July 16, 2026 | 442.56M |
| July 15, 2026 | 450.57M |
| July 14, 2026 | 483.42M |
| July 13, 2026 | 459.38M |
| July 10, 2026 | 443.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
| Sangamo Therapeutics, Inc. | 51.77M |
| Sarepta Therapeutics, Inc. | 2.381B |
| Anixa Biosciences, Inc. | 80.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -56.45M |
| Total Expenses (Quarterly) | 56.45M |
| EPS Diluted (Quarterly) | -705.20 |
| Earnings Yield | -26.43K% |
| Normalized Earnings Yield | -26427.17 |